- Home
- / Black Diamond Therapeutics
Black Diamond Therapeutics
Stock Price
$4.2
2024-09-27
Market Capitalization
$239 M
2024-09-27
Black Diamond Therapeutics Summary
Company Summary
- Overview
- Black Diamond Therapeutics is a biotechnology company. It is focused on the development of selective medicines for patients with genetically-defined cancers driven by oncogenes activated by allosteric mutations.
- Type
- Public
- Status
- Active
- Founded
- 2017
- HQ
- Cambridge, MA, US | view all locations
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Elizabeth Buck, Co-Founder, Chief Scientific Officer
Shannon Campbell, Director
Brent Hatzis-Schoch, Chief Operating Officer, General Counsel
Operating MetricsView all
Patent Applications
7
Jan, 2020
LocationsView all
4 locations detected
Cambridge, MA HQ
United States
1 Main St
New York, NY
United States
180 Varick St 6th floor
Stony Brook, NY
United States
25 Health Sciences Drive
Toronto, ON
Canada
MaRS Centre for Impact Investing, West Tower, 661 University Ave Suite 1300
Black Diamond Therapeutics Financials
Summary Financials
- Net income (Q2, 2024)
- ($19.9M)
- Cash (Q2, 2024)
- $32.8M
- EBIT (Q2, 2024)
- ($22.1M)
- Enterprise value
- $226.7M